^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Excerpt:
...wild type (WT) TP53 status defined as...
Trial ID:
Evidence Level:
Sensitive: D – Preclinical
Title:

First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

Excerpt:
We therefore sought to evaluate the combined antitumor efficacy of ALRN-6924 and paclitaxel or eribulin in ER+ breast cancer with WT TP53...ALRN-6924 was active in wild-type TP53 (WT-TP53) cancer cell lines, but not mutant TP53. On ER+ breast cancer cell lines, it was synergistic in vitro and had enhanced in vivo antitumor activity with both paclitaxel and eribulin….The significant synergy observed with ALRN-6924 in combination with chemotherapeutic agents supports further evaluation in patients with hormone receptor-positive breast cancer.
Secondary therapy:
E7386; bisphosphonate bound paclitaxel
DOI:
10.1186/s13058-021-01406-x